Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

(2009) David A Flockhart et al.   GENETICS IN MEDICINE

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

(2009)   GENETICS IN MEDICINE

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

(2009)   GENETICS IN MEDICINE

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives

(2009)   GENETICS IN MEDICINE

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

Challenges of translating genetic tests into clinical and public health practice

(2009) Wolf H. Rogowski et al.   NATURE REVIEWS GENETICS

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A Critical Appraisal of the Scientific Basis of Commercial Genomic Profiles Used to Assess Health Risks and Personalize Health Interventions

(2008) A. Cecile J.W. Janssens et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Genetic Testing for Warfarin Therapy Initiation

(2008) Lauren M Hynicka et al.   ANNALS OF PHARMACOTHERAPY

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Warfarin and Pharmacogenomic Testing: The Case for Restraint

(2008) DA Garcia   CLINICAL PHARMACOLOGY & THERAPEUTICS

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Critical Path of Warfarin Dosing: Finding an Optimal Dosing Strategy Using Pharmacogenetics

(2008) LJ Lesko   CLINICAL PHARMACOLOGY & THERAPEUTICS

Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis

(2008) Scott D Grosse et al.   GENETICS IN MEDICINE

Legal update: living with the Genetic Information Nondiscrimination Act

(2008) Cheryl Erwin   GENETICS IN MEDICINE

Cost of Care for Elderly Cancer Patients in the United States

(2008) K. Robin Yabroff et al.   JNCI-Journal of the National Cancer Institute

Coverage With Evidence Development

(2008) Franklin G. Miller et al.   MEDICAL CARE

Saying No Isn't NICE — The Travails of Britain's National Institute for Health and Clinical Excellence

(2008) Robert Steinbrook   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

(2008) Ute I. Schwarz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Warfarin Pharmacogenetics

(2008) Nita A Limdi et al.   PHARMACOTHERAPY

Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation

(2008) Surrey M Walton et al.   PHARMACOTHERAPY

Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer?

(2008) Jessica T Lee et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research